Library Item - Page 42 of 792 Posts on Medivizor
Navigation Menu

Library Item Posts on Medivizor

Evaluating the effectiveness of EGFR-TKIs first-line treatment and performance status in older patients with EGFR-mutant NSCLC.

Evaluating the effectiveness of EGFR-TKIs first-line treatment and performance status in older patients with EGFR-mutant NSCLC.

Posted by on Oct 31, 2021 in Lung cancer | 0 comments

In a nutshell This study evaluated the effectiveness of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) first-line treatment and performance status in older patients with EGFR-mutant non-small-cell lung cancer (NSCLC). The data showed that older patients with EGFR-mutated NSCLC who received EGFR-TKI first-line treatment with a...

Read More

Which type of CAR T cell therapy is best for patients with relapsed or refractory large B cell lymphoma?

Which type of CAR T cell therapy is best for patients with relapsed or refractory large B cell lymphoma?

Posted by on Oct 26, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell The authors compared the safety and effectiveness of lisocabtagene maraleucel (liso-cel; Breyanzi) and axicabtagene ciloleucel (axi-cel; Yescarta) in patients with relapsed or refractory (r/r) large B cell lymphoma (LBCL). The study found that both treatments were similarly effective but liso-cel was better tolerated in these...

Read More

Comparing pessaries and disposable continence devices for managing stress incontinence

Comparing pessaries and disposable continence devices for managing stress incontinence

Posted by on Oct 25, 2021 in Urinary incontinence | 0 comments

In a nutshell This study compared two treatments for stress urinary incontinence (SUI), continence pessaries (CP) and disposable intravaginal continence devices (DICD). It found that both treatments reduced symptoms of stress incontinence after 4 weeks in 75-80% of patients. Some background SUI is a condition that commonly affects women...

Read More

Impact of 5-year baricitinib treatment for active, rheumatoid arthritis in preventing radiographic progression of joint damage.

Impact of 5-year baricitinib treatment for active, rheumatoid arthritis in preventing radiographic progression of joint damage.

Posted by on Oct 25, 2021 in Rheumatoid Arthritis | 0 comments

In a nutshell This study evaluated the effect of oral baricitinib (Olumiant) on the prevention of radiographic progression of joint damage over 5 years in patients with active rheumatoid arthritis (RA). The data showed that patients treated with oral baricitinib had less radiographic progression over 5 years, compared to those initially given a...

Read More

Do insulin analogues differ in effectiveness and safety for the treatment of diabetes?

Do insulin analogues differ in effectiveness and safety for the treatment of diabetes?

Posted by on Oct 25, 2021 in Diabetes mellitus | 0 comments

In a nutshell This study assessed the effectiveness and safety of different long-acting and short-acting insulins for the treatment of patients with diabetes. The data supported the use of long-acting insulins instead of neutral protamine Hagedorn (NPH) insulin (Humulin N; Novolin N), as basal insulin for patients with type 2 diabetes (T2D). Some...

Read More

Extended therapy with letrozole for 5 years improves survival outcomes in postmenopausal patients with hormone positive early-stage breast cancer.

Extended therapy with letrozole for 5 years improves survival outcomes in postmenopausal patients with hormone positive early-stage breast cancer.

Posted by on Oct 24, 2021 in Breast cancer | 0 comments

In a nutshell This study compared the effectiveness and safety of extended therapy with letrozole (LET; Femara) for 5 years versus the standard therapy of 2-3 years for the treatment of postmenopausal women with early-stage breast cancer (BC). The data showed that extended treatment with LET for 5 years significantly improved the survival outcomes...

Read More

Evaluating the effectiveness and safety of capecitabine maintenance versus active monitoring for the treatment of patients with metastatic colorectal cancer.

Evaluating the effectiveness and safety of capecitabine maintenance versus active monitoring for the treatment of patients with metastatic colorectal cancer.

Posted by on Oct 24, 2021 in Colorectal cancer | 0 comments

In a nutshell This study investigated the effectiveness and safety of capecitabine (Xeloda) as maintenance therapy versus active monitoring for the treatment of patients with stable metastatic colorectal cancer (mCRC). The data showed that capecitabine maintenance improved survival without cancer worsening with manageable side effects for these...

Read More